Contineum Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Contineum Therapeutics, Inc. (CTNM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 76.74 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-07-30
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 46.84K shares.
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 29.90K shares, a 1108.49% increase year-over-year.
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 44.00K shares.
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 2.53K shares.
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 49.01K shares.
- Contineum Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 46.84K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | 76.74K shares 10-Q · filed 2026-07-30 | 120.74K shares derived: sum of 3 quarters · filed 2026-07-30 | 123.27K shares derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | 29.90K shares 10-Q · filed 2026-05-05 | 73.90K shares derived: sum of 2 quarters · filed 2026-05-05 | 76.43K shares derived: sum of 3 quarters · filed 2026-05-05 | 76.43K shares derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | 44.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 46.53K shares derived: sum of 2 quarters · filed 2026-03-05 | 46.53K shares derived: sum of 3 quarters · filed 2026-03-05 | 49.01K shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 2.53K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | 2.53K shares derived: sum of 2 quarters · filed 2025-10-30 | 5.01K shares 10-Q · filed 2025-10-30 | 5.01K shares derived: sum of 4 quarters · filed 2025-10-30 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 2.47K shares 10-Q · filed 2025-08-05 | 2.47K shares derived: sum of 3 quarters · filed 2025-08-05 | 2.47K shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 2.47K shares 10-Q · filed 2025-05-14 | 2.47K shares derived: sum of 2 quarters · filed 2025-05-14 | 2.47K shares derived: sum of 3 quarters · filed 2025-05-14 | 2.47K shares derived: sum of 4 quarters · filed 2025-05-14 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 0.00 shares derived: sum of 2 quarters · filed 2025-03-06 | 0.00 shares derived: sum of 3 quarters · filed 2025-03-06 | 0.00 shares 10-K · filed 2025-03-06 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 0.00 shares derived: sum of 2 quarters · filed 2024-11-06 | 0.00 shares 10-Q · filed 2024-11-06 | |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 0.00 shares 10-Q · filed 2024-08-14 | ||
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |